PT-141 10mg
LatestLOT PT0002
99.91%HPLC purity · meets spec
- Labeled
- 10mg
- Measured
- 10.61mg
- Identity
- Confirmed
- Heavy metals
- Not Detected
- Sterility
- No Growth
- Endotoxin
- < 0.05 EU/mL
- Tested
- Jul 30, 2026
8 assays passed · ISO/IEC 17025 accredited
Cellular Peptide
PT-141
BremelanotideVyleesiAc-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OHCAS: 189691-06-3
A 7-amino acid cyclic peptide analog of alpha-MSH that activates melanocortin receptors MC3R and MC4R, FDA-approved for hypoactive sexual desire disorder and studied for sexual function in clinical studies. Premium Direct-Supply Peptide.
MassChoose an option
Quantity
From$58
Fast, protected deliveryTracked USA shipping with discreet packaging.
Tracked USA delivery
Free shipment protection
Priority shipping available
Verified Test Results
Every batch, independently verified.
Each batch is analyzed by an ISO/IEC 17025 accredited third-party laboratory. The report below reflects the identity, purity and full-panel specification data reported by the lab.
ILSILS LaboratoriesCertificate of Analysis≥99%Purity by HPLC
ISO 17025 Accredited8× Tested
ParameterResultMethodSpecification
Peptide Purity (HPLC)99.91%HPLC>= 95%
Net Peptide Content10.61mgHPLCReport
Identity (HPLC)ConfirmedHPLCMeets spec
AppearanceGoodVisualMeets spec
Fentanyl ScreenNot DetectedImmunoassayPass
Heavy Metals (ICP-MS)Not DetectedICP-MSPass
Sterility (PCR)No GrowthPCRPass
Endotoxin (USP <85>)< 0.05 EU/mLUSP <85>Reported
Third-Party Verified
Certificate of Analysis
Every lot is HPLC-tested at an ISO/IEC 17025-accredited lab. Open any batch's certificate below.
Frequently Paired Products
Products commonly selected alongside this item
Compound Information
Technical specifications
MOLECULAR PROFILE
What Is PT-141?
Cyclic heptapeptide analog of alpha-MSH, active metabolite of Melanotan II
Cyclic PeptideFDA Approved
- Type
- Cyclic heptapeptide
- CAS Number
- 189691-06-3
- Molecular Formula
- C50H68N14O10
- Molecular Weight
- 1025.2 g/mol
- Amino Acids
- 7 residues
- Sequence
- Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-OH
STORAGE REQUIREMENTS
Stability Information
Handle with care to maintain potencyLight sensitiveRefrigerate
Lyophilized (powder)2-8°Cprotect from light
Reconstituted2-8°C
Auto-injector (Vyleesi)Room temperature
DEVELOPMENT STATUS
Regulatory Information
Developed by Palatin Technologies, approved by FDA
- Developer
- Palatin Technologies
- Marketing
- AMAG Pharmaceuticals
- FDA Approval
- June 21, 2019
- Trade Name
- Vyleesi
- Indication
- HSDD in premenopausal women
- Male Use
- Not approved (product only)
Product Guides & References
Verified publications and source documentation
OBSTETRICS & GYNECOLOGY
Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials
2019•DOI: 10.1097/AOG.0000000000003500•PMID: 31599840Kingsberg SA, Clayton AH, Portman D, et al.
View Source INTERNATIONAL JOURNAL OF IMPOTENCE productPT-141: a melanocortin agonist for the treatment of sexual dysfunction
2004•PMID: 12851303Diamond LE, Earle DC, Rosen RC, et al.
View Source JOURNAL OF SEXUAL MEDICINEAn effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist
2006•DOI: 10.1111/j.1743-6109.2006.00268.x•PMID: 16839319Diamond LE, Earle DC, Heiman JR, et al.
View Source JOURNAL OF WOMEN'S HEALTHReported Event Profile of Bremelanotide Across the Clinical Development Program
2022
View Source FDAVyleesi (bremelanotide) Prescribing Information
2019
View Source MEDICINA (KAUNAS)Bremelanotide for Treatment of Female Hypoactive Sexual Desire Disorder
2022•PMID: 35056399
View Source PUBCHEM DATABASE
